Saccharomyces cerevisiae-based probiotic as novel anti-microbial agent for therapy of bacterial vaginosis
- PMID: 29683763
- PMCID: PMC6037478
- DOI: 10.1080/21505594.2018.1464362
Saccharomyces cerevisiae-based probiotic as novel anti-microbial agent for therapy of bacterial vaginosis
Abstract
In this study, we demonstrate, for the first time, that Saccharomyces cerevisiae-based probiotic shows an inhibitory effect on Gardnerella vaginalis infection. This effect is likely due to several actions: direct interference with adherence to vaginal tissues, inhibition of sialidase activity, reduction of vaginal epithelial exfoliation. Gardnerella vaginalis does not induce vaginal inflammation and no inflammatory cytokines were, indeed, produced, by the mouse vagina, neither by Gardnerella vaginalis and by the probiotic. Collectively, our data incite to further investigations on Saccharomyces cerevisiae probiotic as a potential prophylactic or therapeutic agent in the vaginosis caused by Gardnerella vaginalis.
Keywords: G. vaginalis; S. cerevisiae; adherence; bacterial vaginosis; displacement; exfoliation; probiotic; sialidase.
Figures
References
-
- Leitich H, Bodner-Adler B, Brunbauer M, et al.. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 2003, 189(1):139–47. PubMed PMID:12861153. - PubMed
-
- Rothman KJ, Funch DP, Alfredson T, et al.. Randomized field trial of vaginal douching, pelvic inflammatory disease and pregnancy. Epidemiology. 2003, 14(3):340–8. PubMed PMID:12859036. - PubMed
-
- Jacobsson B, Pernevi P, Chidekel L, et al.. Bacterial vaginosis in early pregnancy may predispose for preterm birth and postpartum endometritis. Acta Obstet Gynecol Scand. 2002, 81(11):1006–10. PubMed PMID:12421167. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources